The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients

M. Scartozzi, A. Sobrero, G. Gasparini, R. Berardi, V. Catalano, F. Graziano, S. Barni, A. Zaniboni, G. D. Beretta, R. Labianca, S. Cascinu

Research output: Contribution to journalArticle

Abstract

Objectives: Although several evidences have demonstrated a synergistic activity of 5-fluorouracil with irinotecan and oxaliplatin, thus explaining the use of this drug combination in the first-line treatment of advanced colorectal cancer, the need for the reintroduction of 5-FU in the second-line setting is more questionable. Methods: We retrospectively evaluated the outcome of patients developing progressive disease while on an infusional 5-FU-based front-line chemotherapy and subsequently treated with one of the four following chemotherapy regimens: irinotecan, oxaliplatin and irinotecan or oxaliplatin both combined with the de Gramont schedule (LV5-FU2). Results: 225 patients (137 males and 88 females), were eligible for analysis. Second-line chemotherapy consisted of irinotecan in 79 patients (35%, group A), oxaliplatin in 47 patients (21%, group B), irinotecan with LV5-FU2 in 53 patients (24%, group C) and oxaliplatin with LV5-FU2 in the remaining 46 cases (20%, group D). The response rate to second-line chemotherapy was obtained in 6/79 patients (8%) in group A, in 4/47 patients (9%) in group B, in 11/53 patients (21%) in group C and in 10/46 patients (22%) in group D (p = 0.04). Conclusions: These data suggest that reintroduction of 5-FU could increase irinotecan and oxaliplatin activity in patients progressing during a 5-FU-based first-line chemotherapy.

Original languageEnglish
Pages (from-to)212-216
Number of pages5
JournalOncology
Volume68
Issue number2-3
DOIs
Publication statusPublished - Jul 2005

Fingerprint

oxaliplatin
irinotecan
Fluorouracil
Colorectal Neoplasms
Drug Therapy

Keywords

  • 5-Fluorouracil
  • Colorectal cancer
  • Second-line chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients. / Scartozzi, M.; Sobrero, A.; Gasparini, G.; Berardi, R.; Catalano, V.; Graziano, F.; Barni, S.; Zaniboni, A.; Beretta, G. D.; Labianca, R.; Cascinu, S.

In: Oncology, Vol. 68, No. 2-3, 07.2005, p. 212-216.

Research output: Contribution to journalArticle

Scartozzi, M, Sobrero, A, Gasparini, G, Berardi, R, Catalano, V, Graziano, F, Barni, S, Zaniboni, A, Beretta, GD, Labianca, R & Cascinu, S 2005, 'The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients', Oncology, vol. 68, no. 2-3, pp. 212-216. https://doi.org/10.1159/000086776
Scartozzi, M. ; Sobrero, A. ; Gasparini, G. ; Berardi, R. ; Catalano, V. ; Graziano, F. ; Barni, S. ; Zaniboni, A. ; Beretta, G. D. ; Labianca, R. ; Cascinu, S. / The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients. In: Oncology. 2005 ; Vol. 68, No. 2-3. pp. 212-216.
@article{c525fbfa91f946c588d9f8c631a573c4,
title = "The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients",
abstract = "Objectives: Although several evidences have demonstrated a synergistic activity of 5-fluorouracil with irinotecan and oxaliplatin, thus explaining the use of this drug combination in the first-line treatment of advanced colorectal cancer, the need for the reintroduction of 5-FU in the second-line setting is more questionable. Methods: We retrospectively evaluated the outcome of patients developing progressive disease while on an infusional 5-FU-based front-line chemotherapy and subsequently treated with one of the four following chemotherapy regimens: irinotecan, oxaliplatin and irinotecan or oxaliplatin both combined with the de Gramont schedule (LV5-FU2). Results: 225 patients (137 males and 88 females), were eligible for analysis. Second-line chemotherapy consisted of irinotecan in 79 patients (35{\%}, group A), oxaliplatin in 47 patients (21{\%}, group B), irinotecan with LV5-FU2 in 53 patients (24{\%}, group C) and oxaliplatin with LV5-FU2 in the remaining 46 cases (20{\%}, group D). The response rate to second-line chemotherapy was obtained in 6/79 patients (8{\%}) in group A, in 4/47 patients (9{\%}) in group B, in 11/53 patients (21{\%}) in group C and in 10/46 patients (22{\%}) in group D (p = 0.04). Conclusions: These data suggest that reintroduction of 5-FU could increase irinotecan and oxaliplatin activity in patients progressing during a 5-FU-based first-line chemotherapy.",
keywords = "5-Fluorouracil, Colorectal cancer, Second-line chemotherapy",
author = "M. Scartozzi and A. Sobrero and G. Gasparini and R. Berardi and V. Catalano and F. Graziano and S. Barni and A. Zaniboni and Beretta, {G. D.} and R. Labianca and S. Cascinu",
year = "2005",
month = "7",
doi = "10.1159/000086776",
language = "English",
volume = "68",
pages = "212--216",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "2-3",

}

TY - JOUR

T1 - The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients

AU - Scartozzi, M.

AU - Sobrero, A.

AU - Gasparini, G.

AU - Berardi, R.

AU - Catalano, V.

AU - Graziano, F.

AU - Barni, S.

AU - Zaniboni, A.

AU - Beretta, G. D.

AU - Labianca, R.

AU - Cascinu, S.

PY - 2005/7

Y1 - 2005/7

N2 - Objectives: Although several evidences have demonstrated a synergistic activity of 5-fluorouracil with irinotecan and oxaliplatin, thus explaining the use of this drug combination in the first-line treatment of advanced colorectal cancer, the need for the reintroduction of 5-FU in the second-line setting is more questionable. Methods: We retrospectively evaluated the outcome of patients developing progressive disease while on an infusional 5-FU-based front-line chemotherapy and subsequently treated with one of the four following chemotherapy regimens: irinotecan, oxaliplatin and irinotecan or oxaliplatin both combined with the de Gramont schedule (LV5-FU2). Results: 225 patients (137 males and 88 females), were eligible for analysis. Second-line chemotherapy consisted of irinotecan in 79 patients (35%, group A), oxaliplatin in 47 patients (21%, group B), irinotecan with LV5-FU2 in 53 patients (24%, group C) and oxaliplatin with LV5-FU2 in the remaining 46 cases (20%, group D). The response rate to second-line chemotherapy was obtained in 6/79 patients (8%) in group A, in 4/47 patients (9%) in group B, in 11/53 patients (21%) in group C and in 10/46 patients (22%) in group D (p = 0.04). Conclusions: These data suggest that reintroduction of 5-FU could increase irinotecan and oxaliplatin activity in patients progressing during a 5-FU-based first-line chemotherapy.

AB - Objectives: Although several evidences have demonstrated a synergistic activity of 5-fluorouracil with irinotecan and oxaliplatin, thus explaining the use of this drug combination in the first-line treatment of advanced colorectal cancer, the need for the reintroduction of 5-FU in the second-line setting is more questionable. Methods: We retrospectively evaluated the outcome of patients developing progressive disease while on an infusional 5-FU-based front-line chemotherapy and subsequently treated with one of the four following chemotherapy regimens: irinotecan, oxaliplatin and irinotecan or oxaliplatin both combined with the de Gramont schedule (LV5-FU2). Results: 225 patients (137 males and 88 females), were eligible for analysis. Second-line chemotherapy consisted of irinotecan in 79 patients (35%, group A), oxaliplatin in 47 patients (21%, group B), irinotecan with LV5-FU2 in 53 patients (24%, group C) and oxaliplatin with LV5-FU2 in the remaining 46 cases (20%, group D). The response rate to second-line chemotherapy was obtained in 6/79 patients (8%) in group A, in 4/47 patients (9%) in group B, in 11/53 patients (21%) in group C and in 10/46 patients (22%) in group D (p = 0.04). Conclusions: These data suggest that reintroduction of 5-FU could increase irinotecan and oxaliplatin activity in patients progressing during a 5-FU-based first-line chemotherapy.

KW - 5-Fluorouracil

KW - Colorectal cancer

KW - Second-line chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=23844537616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844537616&partnerID=8YFLogxK

U2 - 10.1159/000086776

DO - 10.1159/000086776

M3 - Article

C2 - 16015036

AN - SCOPUS:23844537616

VL - 68

SP - 212

EP - 216

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 2-3

ER -